The certificate published for this listing is Janoshik task 66143, batch PP06115: 5.01 mg reported, 99.367% purity, analysed 26 May 2025. Verification key N3LWH77AZYRX. Compare it with the tirzepatide certificate, which is a different batch and a different compound. The product page is semaglutide.
Semaglutide is a synthetic analogue of glucagon-like peptide-1. In published work it is described as a GLP-1 receptor agonist with modifications that slow enzymatic breakdown and extend time in circulation.
Mechanism described in the papers
GLP-1 receptor activation is studied in pancreatic, gastric, and central nervous system models. The literature links that signalling to glucose-dependent insulin release, slowed gastric emptying, and appetite-related pathways. Those are research findings from controlled studies, not instructions.
Research material versus an approved drug
Approved semaglutide medicines are manufactured, labelled, and prescribed under drug regulations. A research peptide is a laboratory reagent. Purity by HPLC and identity by mass spectrometry are the relevant quality checks. They do not make the vial an approved treatment.
- GLP-1 receptor agonist in the published literature
- Distinct from tirzepatide, which also targets the GIP receptor
- COA confirms batch identity and purity, not a clinical use
- Sold for laboratory research only
This article is for educational and research purposes only. Semaglutide sold by Kirei Clinic is not for human use.